News and Trends 15 Jan 2018 British Biotech’s Technology is Taken by Pharma to Fight Alzheimer’s …Modular Antibody Technology, which introduces an extra antigen-binding site into the constant region of an antibody to create Fcabs that can then bind transporters in the blood-brain barrier. These can… January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2020 Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease,… April 2, 2020 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2025 XOMA Royalty’s acquisition of Turnstone Biologics: what do royalty deals offer the biopharma industry? …to BioInvent in exchange for upsizing our royalty.” The antibody drug was born from BioInvent’s n-CoDeR antibody library containing more than 30 billion human antibody genes stored within phage viruses… July 11, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy …preclinical testing of the antibody and conduct a Phase I trial. Tusk’s anti-CD38 antibody could help to make CD38 a target for not only hematological malignancies but for solid tumours… November 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jun 2021 Scotland’s Top 10 Biotech Companies to Watch Out For …treatments using antibody-like immune proteins from sharks. These shark-derived proteins are smaller and stabler than conventional antibodies; this means they can hit different targets to those of regular antibodies and… June 30, 2021 - 11 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs …the company’s efforts to complete the phase 2 clinical development of its antibody, known as AntiBKV, which is designed to combat BK polyomavirus (BKV) infections in kidney transplant recipients. The… November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2018 Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema …the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against the human placental… July 20, 2018 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2019 Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents …to CD38 for the treatment of cancer, including multiple myeloma. MOR202 induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of multiple myeloma cells. (Source: MorphoSys) With… January 28, 2019 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 May 2024 8 Swedish companies spearheading the country’s biotech scene …precisely identifying antibodies that bind to the specific target protein easier, the Lund-headquartered company’s antibody library n-CoDeR contains more than 30 billion human antibody genes stored within phages in test… May 28, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2018 Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have shown positive results in clinical trials, and have attracted Janssen… December 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 An Antibody to reduce Hospitalizations of Children starts Phase IIb trials Ablynx has treated its first patient in a new trial targeting RSV infections, the main cause of children hospitalizations. Ablynx, one of the few European biotechs that made it into… January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Aug 2025 Five biotech companies in South Korea you should know about …bind to targets. The most advanced antibody in IMBiologics’ roster is IMB-101, which hit the clinic two months ago. It is a bispecific antibody targeting OX40L and TNF, which modulates both… August 26, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email